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Epistatic Modifiers of Autoimmunity
in a Murine Model of Lupus Nephritis
disease. Although NZB develops hemolytic autoimmu-
nity and NZW, a mild, late onset autoimmune nephritis,
the severe autoimmune phenotype expressed in their
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and Laboratory Medicine F1 hybrid is much greater than predicted by the additive
²Center for Mammalian Genetics expression of the parental phenotypes, suggesting a
College of Medicine role for genetic interactions, commonly termed epista-
University of Florida sis, in the generation of disease susceptibility.
Gainesville, Florida 32610 Our studies have focused on the genetic dissection
of the lupus-prone NZM2410 mouse model of SLE. This
severely lupus-prone strain is 1 of 27 congenic recom-
binant strains (termed NZM for New Zealand Mixed)Summary
produced by Rudofsky and coworkers by inbreeding
(NZB 3 NZW)F1 3 NZW backcross progeny (RudofskySle1 and Sle3 are NZW-derived loci that mediate lupus
nephritis on a C57BL/6 background. The absence of et al., 1993). We previously defined the genomic posi-
severe autoimmunity in NZW suggests that the NZW tions of three recessive loci (designated Sle1, Sle2, and
genome suppresses these genes. (B6.NZMc1[Sle1] 3 Sle3) that are strongly associated with lupus susceptibil-
NZW)F1 hybrids develop severe humoral autoimmu- ity in NZM2410 (Morel et al., 1994). In subsequent stud-
nity and fatal lupus nephritis, indicating that suppres- ies, we produced a collection of congenic strains car-
sion of Sle1 from NZW is recessive. Linkage analysis rying these NZM2410-derived chromosomal segments
identified four epistatic modifiers, Sles1-4, whose cu- on a B6 background (Morel et al., 1996) and used them
mulative effect accounted for the benign autoimmu- to characterize the component phenotypes associated
nity in NZW. The specific suppression of Sle1 but not with each SLE susceptibility gene (Morel et al., 1997).
Sle2 or Sle3 by Sles1 was directly demonstrated via These studies determined (1) that Sle1, carried by the
the production and analysis of bicongenic strains. congenic strain B6.NZMc1, mediates a spontaneous
Moreover, Sles1 was sufficient to completely suppress loss of immunologic tolerance to nuclear antigens (Mo-
autoimmunity initiated by Sle1 in B6.NZMc1 3 NZW han et al., 1998); (2) that Sle2, carried by B6.NZMc4,
hybrids. These results demonstrate the complex epi- lowers the activation threshold of the B cell compart-
static interactions of loci augmenting and suppressing ment and mediates polyclonal/polyreactive antibody
systemic autoimmunity. production (Mohan et al., 1997); and (3) that Sle3, carried
by B6.NZMc7, mediates a dysregulation of the T cell
compartment that potentiates polyclonal IgG antibody
Introduction production and decreases activation-induced cell death
in CD4 T cells (Morel et al., 1997; Mohan et al., 1999b).
Systemic lupus erythematosus (SLE) is a chronic auto- More recently, we have produced a collection of bi-
immune disease characterized by the development of congenic strains carrying these susceptibility alleles in
systemic autoimmunity and the production of autoanti- various combinations to assess the role of genetic inter-
bodies to a spectrum of nuclear antigens. The most actions in the development of severe disease. An analy-
severe clinical consequences of SLE are associated with sis of B6.NZMc1|c7, which carries Sle1 and Sle3 in com-
immune complex deposition in the kidney, resulting in bination, revealed that these two susceptibility genes
lupus nephritis and culminating in kidney failure. Al- are sufficient to mediate the development of severe hu-
though the factors responsible for the development of moral autoimmunity and fatal lupus nephritis on the B6
SLE in human patients are poorly understood, a wealth background (Mohan et al., 1999a). B6.NZMc1|c7 ani-
of data strongly support the hypothesis that SLE sus- mals spontaneously develop high titers of autoantibody
ceptibility is inherited as a multifactorial genetic disease directed against a broad spectrum of nuclear chromatin
(Winchester, 1992; Gaffney et al., 1998; Harley et al., autoantigens and die of kidney failure (penetrance .55%)
1998; Moser et al., 1998). due to autoimmune glomerulonephritis (GN) within 12
Over the past 30 years, murine models of SLE have months of age.
contributed significantly to our understanding of the The lethal phenotype produced by the combination
disease (reviewed in Theofilopoulos and Dixon, 1985;
of Sle1 and Sle3 on the B6 background was somewhat
Theofilopoulos, 1993; Wakeland et al., 1997). An intrigu-
surprising, in that both of these genes are derived from
ing aspect of the genetics of the classic (NZB 3 NZW)F1
the relatively unaffected NZW strain (Morel et al., 1996),
hybrid murine model of SLE has been the requirement
suggesting that their severe autoimmune phenotypesof an F1 hybrid genome for the development of severe
must be suppressed in some manner by the NZW ge-
nome. Here, we present our genetic analysis of this
³ To whom correspondence should be addressed (email: morel. epistatic suppression in NZW and present the locations
pathology@mail.health.ufl.edu [L. M.], edward.wakeland@email.swmed.
of four SLE suppressor loci (designated Sles1 throughedu [E. K. W.]).
Sles4) that account for the absence of fatal disease in§ Present address: Center for Immunology, University of Texas
Southwestern Medical Center, Dallas, Texas 75235. NZW.
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in NZM2410 is presented in Figure 1. These results dem-
onstrate that Sle1, Sle2, Sle3, and H2 in NZM2410 are
all derived from the NZW parent.
We have previously described the component autoim-
mune phenotypes expressed in B6-congenic strains
carrying Sle1 B6.NZMc1), Sle3 (B6.NZMc7), and Sle11
Sle3 (B6.NZMc1|c7) (Morel et al., 1997; Mohan et al.,
1998, 1999a, 1999b). As shown in Table 1, the autoim-
mune phenotypes expressed by these B6 congenic
strains differ dramatically from the mild autoimmunity
exhibited by NZW. Most notably, Sle1 and Sle3 cause
fatal lupus nephritis when combined on the B6 back-
ground (B6.NZMc1|c7) and yet fail to elicit systemic au-
toimmunity in the parental NZW strain. We hypothesized
that the autoimmune phenotypes of these susceptibility
genes must be suppressed in NZW by recessive epi-
static modifiers, consistent with the classic detection
of severe autoimmunity only in (NZB 3 NZW)F1 hybrids.
To test this possibility, we crossed NZW to B6.NZMc1
and B6, aged the hybrids up to 12 months, and tested
their autoimmune phenotypes. Our expectation was that
B6.NZMc1 3 NZW hybrids would produce anti-H2A/
H2B-DNA autoantibodies, indicating that the putative
Sle1 suppressors in the NZW genome were recessive
modifiers. To our surprise, B6.NZMc1 3 NZW hybrids
developed severe systemic autoimmunity, character-
ized by a potent humoral autoimmune response to a
Figure 1. Relative Contributions of NZB and NZW to the NZM2410
spectrum of nuclear antigens associated with a highlyGenome
penetrant (.75%) fatal lupus nephritis in both sexesOn each chromosome, white rectangles indicate regions where
(Table 1). The severity of the glomerulonephritis in thispolymorphic markers corresponded to the NZW alleles and black
hybrid is comparable to or greater than that seen inrectangles corresponded to the NZB alleles. The positions of the
five Sle loci are indicated on the right. NZM2410. These results indicate that homozygosity for
Sle1 triggers severe systemic autoimmunity in the B6 3
NZW hybrid genome, consistent with the presence of
Results powerful epistatic interactions between genes contrib-
uted by both B6 and NZW. Interestingly, this devastating
Epistatic Activation of Autoimmunity in B6 3 NZW autoimmune disease was totally dependent on homozy-
Hybrids by Homozygosity for Sle1 gosity for Sle1, as demonstrated by the normal pheno-
We have completed an analysis of the parental strain type (serologically and histologically) of Sle1- heterozy-
origin of the entire NZM2410 genome using 218 microsat- gous B6 3 NZW control hybrids (Table 1).
ellite markers distributed throughout all 19 autosomes.
This analysis found that 76.3% of these markers de-
tected NZW alleles in the NZM2410 genome, consistent Interval Mapping of Epistatic Modifiers
of Sle1-Mediated Autoimmunitywith the expected 75% genetic contribution of the recur-
rent NZW parent to the genomes of the NZM congenic To determine the number and locations of epistatic mod-
ifiers interacting with Sle1- homozygosity to mediaterecombinant collection (Rudofsky et al., 1993). The dis-
tribution of NZW and NZB-derived genomic segments severe autoimmunity in B6 3 NZW hybrids, we produced
Table 1. Penetrance of Autoimmune Phenotypes Mediated by Sle1 and Sle3 in Various Combinations and Genomic Contexts
Mice Sle1/Sle3 Genotype Anti-H2A/H2B-DNA IgG Anti-dsDNA IgG Fatal Lupus
B6.NZMc1 Sle1 homo 81% (60) 67% (60) 0% (200)
B6.NZMc7 Sle3 homo 41% (46) 47% (46) 0% (46)
B6.NZMc1|c7 Sle1 homo 85% (63) 85% (63) 55% (63)
Sle3 homo
NZW females Sle1 homo 0% (13) 0% (13) 0% (25)
Sle3 homo
(B6.NZMc1 3 NZW)F1 Sle1homo 85% (26) 85% (26) 85% (27)
Sle3hetero
(B6 3 NZW)F1 Sle1hetero 0% (16) 0% (16) 0% (16)
Sle3 hetero
(B6.NZMc1 3 NZW)F1 X NZW Sle1 homo 46% (272) 42% (272) 36% (260)
Sle3 segregating
Data for B6.NZMc1, B6.NZMc7, and B6.NZMc1|c7 are from Morel et al., 1997, and Mohan et al., 1999a. Numbers in parenthesis refer to
sample size for each phenotype measured.
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Table 2. Genetic Intervals Associated with Autoimmune Phenotypes by a Genome Scan of (B6.NZMc1 3 NZW)F1 3 NZW Backcross
Progeny
Glomerulonephritis IgG Autoantibody Production to dsDNA
Deviation from Exp.b Deviation from Exp.b
Locusa Markers Sample Hom. Het. X2 LOD Sample Hom. Het. X2 LOD
Enhancing D5MIT146 82 12.4 212.4 7.71 1.68 111 8.5 28.5 2.68 0.58
Sle6 D5MIT4 85 18.6 218.6 16.70 3.63 113 13.7 213.7 6.75 1.47
D5MIT233 85 16.8 216.8 13.53 2.94 114 14.4 214.4 7.45 1.62
D5MIT12 85 9.0 29.0 3.86 0.84 113 7.2 27.2 1.84 0.40
D7MIT178 85 9.2 29.2 4.15 0.90 114 12.7 212.7 5.86 1.27
Ckmm 85 14.9 214.9 11.22 2.44 114 21.3 221.3 17.09 3.71
Sle3 D7MIT155 85 20.2 220.2 21.43 4.66 114 27.4 227.4 29.35 6.38
D7MIT158 85 26.4 226.4 37.55 8.16 114 28.0 228.0 31.49 6.85
p 85 25.1 225.1 33.74 7.34 114 27.6 227.6 30.40 6.61
D7MIT70 85 25.2 225.2 33.36 7.25 114 26.4 226.4 27.24 5.92
tyr 85 16.6 216.6 13.51 2.94 114 10.9 210.9 4.33 0.94
D17MIT164 85 219.2 19.2 17.35 3.77 114 217.9 17.9 11.29 2.45
Suppressive H2 84 231.5 31.5 48.28 10.50 113 232.2 32.2 37.57 8.17
Sles1 D17MIT34 85 232.2 32.2 50.16 10.90 114 233.0 33.0 39.27 8.54
D17MIT10 84 224.7 24.7 29.69 6.46 113 224.2 24.2 21.16 4.60
D4MIT9 84 27.1 7.1 2.46 0.53 112 27.8 7.8 2.23 0.49
Sles2 D4MIT12 84 214.2 14.2 9.88 2.15 112 219.6 19.6 14.12 3.07
D4MIT54 83 211.9 11.9 6.91 1.50 110 217.8 17.8 11.70 2.54
D4MIT33 82 211.4 11.4 6.47 1.41 110 216.6 16.6 10.21 2.22
IL2 85 210.1 10.1 4.85 1.05 113 217.4 17.4 10.70 2.33
Sles3 D3MIT137 85 213.1 13.1 8.08 1.76 114 219.5 19.5 13.34 2.90
D3MIT100 84 27.7 7.20 2.83 0.61 113 213.4 13.4 6.40 1.39
D3MIT17 59 26.3 6.3 2.66 0.58 68 0.1 20.1 0.00 0.00
Sles4 D9MIT59 85 213.5 13.5 8.60 1.87 114 210.0 10.0 3.49 0.76
D9MIT249 85 214.9 14.9 10.43 2.27 114 28.8 8.8 2.73 0.59
D9-MIT42 85 214.6 14.6 10.05 2.19 114 211.7 11.7 4.85 1.05
D9MIT90 85 212.6 12.6 7.60 1.65 114 211.5 11.5 4.67 1.01
D9MIT2 85 210.1 10.1 4.84 1.05 114 26.1 6.1 1.31 0.29
a Locus designations for susceptibility loci (Sle) and SLE suppressive loci (Sles) were determined via consultation with the Mouse Genome
Database. Only markers within the 95 support interval for each detected locus are presented.
b Deviations from expected values were calculated based on the expected genotypic ratios in the absence of linkage to the trait, corrected
for observed segregation ratios in an unaffected cohort of backcross animals.
272 (B6.NZMc1 3 NZW) 3 NZW backcross progeny peaking on D5MIT4. This locus, which we have desig-
nated Sle6, was significantly associated with lupus ne-and assessed their autoimmune phenotypes through 12
months of age. As shown in Table 1, 85 of these back- phritis (LOD 3.63) and only weakly associated with hu-
moral autoimmunity (LOD 1.47). As shown in Figure 1,cross progeny developed fatal lupus nephritis and 114
produced high titers of anti-dsDNA autoantibody. The the Sle6 genomic interval is derived from NZB in
NZM2410, consistent with our failure to associate sus-positions of loci contributing to these phenotypes were
determined via a genome scan using 122 informative ceptibility with this region in our previous crosses of B6
and NZM2410.microsatellite markers distributed throughout the au-
tosomal genome. As shown in Table 2, this analysis Four intervals in which heterozygosity was associated
with disease susceptibility in the (B6.NZMc1 3 NZW) 3identified six intervals with either significant or sugges-
tive linkage (Lander and Kruglyak, 1995) to fatal lupus NZW backcross were detected. We propose to desig-
nate these loci with the symbol Sles, for SLE suppressor,or high titered anti-dsDNA autoantibody. These intervals
could be organized into two groups based on whether based on the diminution of autoimmunity by homozy-
gosity for NZW-derived alleles at these loci. The stron-homozygosity or heterozygosity for NZW-derived alleles
was associated with disease. gest of these, designated Sles1, is located on chromo-
some 17 near D17MIT34 in the S (complement) regionDisease susceptibility was enhanced by homozygos-
ity for two NZW-derived genomic intervals. One of these of the murine MHC. Heterozygosity for this interval was
strongly associated with both lupus nephritis (LODwas centered on D7MIT158, which coincides precisely
with the location of Sle3 defined previously (Morel et 10.90) and humoral autoimmunity (LOD 8.54). Previous
linkage analyses in the NZB/W model system by our-al., 1994, 1999). Homozygosity for NZW at this interval
was significantly associated with both lupus nephritis selves and other investigators have reported linkage of
lupus susceptibility with H2 heterozygosity (reviewed in(LOD 8.16) and humoral autoimmunity (LOD 6.85) (Table
2). This finding is similar to our previous analyses of the Drake et al., 1995). Sles2 was centered on D4MIT12 in
the telomeric region of chromosome 4 and was moreproperties of Sle3 in crosses of B6 and NZM2410 and
with the strong disease-associated epistasis of Sle1 and strongly associated with humoral autoimmunity (LOD
3.07) than lupus nephritis (LOD 2.15). Interestingly, Sles2Sle3 in B6.NZMc1|c7 bicongenics (Morel et al., 1994,
1999; Mohan et al., 1999a). A second novel locus was is localized in a region of chromosome 4 that was pre-
viously reported to contain NZB-derived susceptibilityidentified in the centromeric region of chromosome 5,
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tively). These results indicate that backcross progeny
lacking any active Sles alleles developed fatal lupus
with a penetrance similar to the susceptible parental F1
hybrid, while backcross progeny with active Sles alleles
at all four loci did not develop disease, indicating that
the combined effect of these four Sles alleles is sufficient
to account for the suppression of autoimmunity in NZW.
Specific Suppression of Sle1-Mediated
Autoimmunity by Sles1
A B6-congenic strain carrying NZW-derived alleles for
both Sle1 and Sles1 was produced by introgressing the
Sles1 support interval from B6.NZMc17 (produced pre-
viously [Morel et al., 1996]) onto B6.NZMc1. Groups of
20 to 25 B6.NZMc1 mice heterozygous or homozygous
for the NZW allele of Sles1 were aged, together with
parental animals, and screened for the spontaneous
production of anti-H2A/H2B-DNA autoantibodies at 9
months of age. As shown in Figure 3A, introgression of
Figure 2. Combined Effect of Sles Loci on the Penetrance of Auto- Sles1 onto B6.NZMc1 completely abrogates the autoim-
immune Phenotypes in Backross Progeny
mune phenotypes mediated by Sle1. The B6.NZMc1|c17
Mice were pooled according to the number (0 to 4) of Sles loci at
bicongenics, which are homozygous for NZW-derivedwhich they were homozygous for the NZW allele. The peak marker
intervals containing Sle1 and Sles1, have a serologicalfor each locus (D17MIT34 for Sles1, D4MIT54 for Sles2, D3MIT137
profile for antinuclear antibody production that is indis-for Sles3, and D9MIT249 for Sles4) was used for this computation.
The numbers of mice in each group were as follows: ª0º 5 24, ª1º 5 tinguishable from that of normal B6 mice. Sles1 suppres-
69, ª2º 5 85, ª3º 5 56, and ª4º 5 8. Penetrance of the (B6.NZMc1 3 sion of Sle1 is strongly recessive (p 5 8 3 1028 ), consis-
NZW)F1 hybrids is shown on the left for comparison. The penetrance tent with the mode of inheritance of Sles1 in the genome
of both GN and anti-dsDNA production was not significantly differ-
scan. Interestingly, these mice also lack the increasedent between the (B6.NZMc1 3 NZW)F1 hybrids and the backcross
frequency of B7.2 high B cells associated with Sle1progeny without any Sles locus. There was a statistically significant
(Sobel et al., 1999), although the suppression of thisnegative correlation between the number of Sles loci and the pene-
trance of GN and anti-dsDNA (ANOVA: F 5 45.06, p 5 0.0067, and phenotype is not fully recessive (Figure 3A). Figures 3B
F 5 41.56, p 5 0.0076, respectively). and 3C demonstrate that homozygosity for Sles1 does
not suppress the autoimmune phenotypes associated
with Sle2 or Sle3, and, if anything, that their phenotypesalleles (Nba1 and Lbw5) in two independent NZB 3 NZW
are increased slightly in mice homozygous for Sles1.test crosses (Drake et al., 1994; Kono et al., 1994). Sles3
These findings indicate that Sles1 homozygosity uniquelypeaked at D3MIT137 in the centromeric region of chro-
suppresses the ability of Sle1 to mediate a break inmosome 3 with heterozygosity reaching suggestive link-
tolerance to nuclear antigens.age for humoral autoimmunity (LOD 2.9) and weaker
Finally, we have tested the ability of homozygosity forlinkage with lupus nephritis (LOD 1.76). Sles3 is near Il2
Sles1 to suppress the initiation of severe autoimmunityin a region of chromosome 3 that has been associated
in (B6.NZMc1 3 NZW)F1 hybrids. To assess this interac-with susceptibility to both diabetes and EAE in other
tion, we produced (B6.NZMc1|c17 3 NZW)F1 hybridsmurine models (reviewed in Vyse and Todd, 1996). Fi-
and compared their autoimmune phenotypes with thosenally, Sles4 is located in the centromeric region of chro-
of (B6.NZMc1 3 NZW)F1. As shown in Figure 4, homozy-mosome 9 near D9MIT249. Heterozygosity for this inter-
gosity for the genomic interval carrying Sles1 from NZWval reached suggestive linkage for lupus nephritis (LOD
fully suppressed the severe autoimmune cascade that2.27) and showed no linkage to humoral autoimmunity
was initiated by homozygosity for Sle1 in (B6.NZMc1 3(LOD 0.59). Interestingly, Sles4 was strongly gender bi-
NZW)F1 hybrids. In addition to protecting this hybridased, in that the entire effect was male specific (LOD
from the development of fatal glomerulonephritis, Sles12.14 for 35 affected males versus LOD 0.72 for 50 af-
suppressed completely the development of humoral au-fected females).
toimmunity and splenomegaly (Figure 4). These resultsMultivariate analysis of disease penetrance as a func-
indicate that Sles1-mediated suppression of Sle1 willtion of suppressive Sles alleles carried supports the
cause the complete termination of the severe autoim-hypothesis that the cumulative effect of these four loci
mune cascade initiated by Sle1 homozygosity in theis sufficient to account for the suppression of severe
B6 3 NZW hybrid genome.autoimmunity in NZW. As shown in Figure 2, the pene-
trance of lupus and humoral autoimmunity in backcross
progeny heterozygous for all four Sles loci is statistically Discussion
indistinguishable from that observed in B6.NZMc1 3
NZW hybrids and progressively decreases as a function These results directly demonstrate the importance of
epistatic interactions between multiple loci in the devel-of the number of Sles loci homozygous for NZW alleles.
The number of active Sles loci was negatively correlated opment of autoimmunity and provide an important in-
sight into the mode of inheritance of autoimmunity. Ourwith the penetrance of GN and anti-dsDNA (ANOVA: F 5
45.06, p 5 0.0067, and F 5 41.56, p 5 0.0076, respec- results indicate that susceptibility to autoimmune lupus
Suppressive Modifiers of Murine Lupus
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Figure 3. Sles1 Suppresses Sle1, but Not Sle2
or Sle3
(A) Left panel: anti-H2A/H2B/DNA IgG pro-
duction mediated by Sle1 in the presence of
0 (B6.NZMc1), 1 (B6.NZMc1|c17 het), and 2
(B6.NZMc1|c17) copies of Sles1. All samples
were tested in a single ELISA assay. Right
panel: expression level of B7.2 on splenic B
cells in the same combinations of Sle1 and
Sles1. Values are expressed relative to the
median value of a C57BL/6 control tested in
each assay. (B) B1a/B2 cell ratios in the peri-
toneal cavities of B6.NZMc4 (Sle2) and
B6.NZMc4|c17 (Sle2 and Sles1) mice. (C)
Anti-dsDNA production in B6.NZMc7 (Sle3)
and B6.NZMc7|c17 (Sle3 and Sles1) mice.
Each dot represents a 9- to 12-month-old
mouse. Comparisons were made using one-
tailed t tests. No significant difference was
found between C57BL/6 and B6.H2z for any
of the four phenotypes shown here.
is dependent upon a complex array of epistatic interac- Perhaps the most intriguing feature of this complex
system is the discovery of epistatic suppressors capa-tions between genes that either enhance or suppress
autoimmunity. As a result, the autoimmune potential of ble of completely suppressing autoimmunity in NZW.
The most potent of these is Sles1, which specificallyany specific susceptibility allele can vary dramatically,
depending upon the genetic context in which it is ex- suppresses the break in immune tolerance to chromatin
caused by Sle1. Our analysis of the interactions of thesepressed. Thus, homozygosity for Sle1 causes a relatively
benign autoantibody production in B6, has apparently two genes in congenic strain combinations directly dem-
onstrates of suppression of autoimmunity by a locus-no autoimmune phenotype in NZW, but is the essential
element in the development of highly penetrant, fatal specific suppressive modifier. This result is consistent
with the hypothesis that Sles1 and Sle1 encode productslupus nephritis in an F1 hybrid of these two genomes.
This illustrates the tremendous variation in phenotype that impact the same pathway, although further research
will be required to elucidate the molecular events thatthat can result when a susceptibility gene is incorpo-
rated into different genomes. Furthermore, these find- mediate this interaction. Interestingly, Sles1 was capa-
ble of completely inhibiting the autoimmune cascadeings suggest that identifying individuals at risk for the
development of autoimmunity in outbred populations initiated by Sle1 homozygosity in the B6/NZW hybrid
genome. This result supports the notion that suppres-via genetic diagnostics may be extremely challenging.
For example, in this simple collection of inbred mice, sion of a key susceptibility gene (or the pathway in which
it functions) potentially can fully suppress autoimmunity.susceptibility alleles for Sle1, Sle2, and Sle3 are present
in both NZM2410 and NZW, yet only one of these two However, several (B6.NZMc1 3 NZW) 3 NZW backcross
progeny that were homozygous for Sles1 still developedstrains is significantly at risk for the development of
lupus nephritis. Thus, an accurate identification of ge- fatal lupus nephritis, indicating that one suppressive
modifier is not sufficient to suppress this disease innetically predisposed individuals in an outbred popula-
tion will require extensive knowledge of all the genes every genomic context. A second important observation
is that the combined effects of all the Sles genes de-impacting autoimmune pathways and an understanding
of the specific allelic interactions that mediate disease tected can fully suppress autoimmune lupus in this sys-
tem and that penetrance varies in a cumulative fashion.development.
Immunity
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Figure 4. Sles1 Prevents Autoimmunity in
(NZW 3 B6.NZMc1)F1
NZW was crossed to B6.NZMc1|c17, re-
sulting in NZW homozygosity at Sle1 and
Sles1, and NZW/C57BL/6 heterozygosity on
the rest of the genome. Upper panel: PAS
stains (3400) of (B6.NZMc1|c17 3 NZW)F1
and C57BL/6 kidneys. This figure shows that
both strains have normal glomeruli. The capil-
lary loops are widely patent. There is no cell
proliferation or inflammation in the glomeruli,
tubules, or interstitium. The severe kidney pa-
thology displayed by B6.NZMc1 3 NZW mice
includes hypercellular glomeruli with inflam-
matory cells, mononuclear (lymphohistiocys-
tic) intersticial infiltrates, and large crescents
in Bowman's space (data not shown). Lower
panel: anti-H2A/H2B/DNA antibody produc-
tion and spleen weights in (B6.NZMc1|c17 3
NZW)F1 and (B6.NZMc1| 3 NZW)F1, show-
ing that the expression of Sles1 reduces
(B6.NZMc1 3 NZW)F1 autoimmune pheno-
types to C57BL/6 background levels.
This observation indicates that the autoimmune predis- (Winchester, 1992; Jacob et al., 1996). In this regard,
the peak suppressive association in the genome scanposition of these mice reflects a complex interaction of
alleles that both potentiate and inhibit autoimmunity. was with a marker within the S rather than IA region of
H2, thus favoring complement and/or TNF genes asClearly, identifying the precise genes involved and eluci-
dating the mechanisms by which they impact the im- candidates for Sles1 effects. However, the classic inter-
pretation of our findings would be that Sles1 suppres-mune system should provide valuable targets with which
to modulate autoimmunity. sion is due to variations in antigen presentation by the
H2z-encoded class II molecules. Theoretically, if IAz andThe presence of H2z within the support interval for
Sles1 is an intriguing result that is consistent with the IEz molecules were incapable of presenting a key au-
toantigen for the initiation of systemic autoimmunity,findings of several previous genetic analyses of suscep-
tibility in the NZB/W system. Enhanced susceptibility to this could result in a failure of H2z homozygotes to initiate
an autoimmune response. Although this possibility can-disease has been consistently associated with heterozy-
gosity for H2 in the NZB/W system (Vyse and Kotzin, not be discounted without further investigation, some
aspects of the functional properties of Sle1 and Sles11998). Our analysis of Sles1 is consistent with this in
that Sles1-mediated suppression of the autoimmune argue against this interpretation. For example, the H2z
haplotype is capable of presenting antigens during thecascade initiated by Sle1 is eliminated in H2 heterozy-
gotes. Thus, at least in our system, it appears that H2z initiation of disease in the lupus-prone NZM2410 paren-
tal strain, which clearly involves the generation of a po-heterozygosity becomes associated with susceptibility
due to the activation of the Sle1 pathway. However, tent autoreactive T cell response in the context of H2z
antigen-presenting molecules. Furthermore, our analy-our analysis of the impact of H2 on other autoimmune
phenotypes suggests that H2 heterozygosity may also sis of antigen recognition by autoimmune T cells in
B6.NZMc1 (Sle1) mice indicates that the T cell compart-enhance the phenotypes of other lupus susceptibility
genes (Morel et al., 1996; Figure 3). Thus, H2 may play ment has lost tolerance to several different histone pro-
teins (Mohan et al., 1998). Similarly, the Sles1-H2z inter-multiple roles in potentiating and/or suppressing auto-
immunity in the NZB/W system. val specifically suppresses Sle1 but fails to inhibit the
autoimmune phenotype of Sle3, which also producesSeveral genes within the H2 region may contribute
to these effects. Most notably, TNFa and complement autoantibody to nuclear antigens (Morel et al., 1997).
Also, we have recently shown that Sle1 must be ex-components are potential candidates, both of which
have been implicated in lupus susceptibility previously pressed in a B cell to cause that B cell to produce
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Figure 5. Model of SLE Pathogenesis as a
Progression of Three Successive Stages
Based on our congenic dissection of the
NZM2410 model (Mohan et al., 1997, 1998,
1999a, 1999b; Morel et al., 1997) and the re-
sults reported here, the positions of the Sle
loci in this progression are indicated on the
top, and the resulting phenotypes are de-
scribed on the bottom. The position of Sles1
as interfering with the ability of Sle1 to medi-
ate a loss of immune tolerance to chromatin
is based on the normal phenotype of
B6.NZMc1|c17.
autoantibodies, consistent with a role in B cell biology, We would propose that each of these will impact autoim-
munity via suppressive effects in one of these pathways.rather than T cell activation (Sobel et al., 1999). Finally,
Our analysis of the interactions of Sles1 and Sle1 indi-Kotzin and coworkers have recently produced trans-
cate that this suppressive modifier specifically inhibitsgenic strains expressing Az and/or Ez molecules and
Sle1, consistent with its placement in the pathway lead-failed to identify any significant effect of transgenic ex-
ing to a loss of tolerance to chromatin antigens. Interest-pression of these molecules on autoimmunity (Vyse et
ingly, the suppression of this pathway by Sles1 inal., 1998; Rozzo et al., 1999). Taken together, these prop-
(B6.NZMc1 3 NZW)F1 hybrids results in the completeerties argue against a failure in antigen presentation as
abrogation of disease, indicating that inhibition of anan explanation for the suppression of Sle1 by Sles1.
Sle1-mediated break in tolerance to chromatin can ter-However, further experiments will be required to delin-
minate the autoimmune cascade detected in this modeleate the mechanism by which Sles1 inhibits Sle1-medi-
system. The specific pathways effected by Sles2-4 willated autoimmunity.
require further analysis via congenic dissection. Clearly,Figure 5 presents our current working model for the
elucidating these interactions will provide important in-genetics of autoimmune lupus, which we hypothesize
sights into the pathogenic processes that mediate lupusinvolves epistatic interactions between genes in three
nephritis.separate genetic pathways. First, the initiation of auto-
Recent studies indicate that the genetic basis for SLEimmunity is mediated by genes such as Sle1 that trigger
susceptibility in humans will be inherited as a multifacto-the loss of immune tolerance to nuclear autoantigens.
rial trait (Tsao et al., 1997; Gaffney et al., 1998; HarleyGenes in this pathway are capable of causing the initia-
et al., 1998; Moser et al., 1998). Most interestingly, strongtion of a humoral autoimmune response to nuclear anti-
linkage to SLE susceptibility in African-American fami-gens; however, this response is not pathogenic in the
lies has been reported for the region of human chromo-absence of genes in the other pathways. In this regard,
some 1 that is syntenic with Sle1 (Salmon et al., 1996;many first degree relatives of SLE probands exhibit a
Wu et al., 1997; Moser et al., 1998). Further work will besimilar seropositive phenotype without severe disease
needed to determine whether the human homolog ofpathogenesis (Winchester, 1992). The second genetic
Sle1 is involved in lupus susceptibility in humans. The
pathway mediating lupus susceptibility contains genes
key role that Sle1 plays in the loss of immune tolerance
causing generalized immune hyperresponsiveness or
to nuclear antigens in the NZB/W model supports the
dysregulation. Genes such as Sle2 (Mohan et al., 1997), notion that Sle1 and Sles1 are members of a genetic
Sle3 (Morel et al., 1997; Mohan et al., 1999b), lpr (Cohen pathway that will be central in the development of dis-
and Eisenberg, 1991), gld (Cohen and Eisenberg, 1991), ease pathogenesis in humans.
and Yaa (Izui et al., 1994) would all be included in this Given the complexity of the immune system, it is rea-
pathway. These genes often do not generate autoim- sonable to predict that epistasis may also impact SLE
mune phenotypes in lupus-resistant genomes but strongly susceptibility in humans. Such interactions will provide
enhance the expansion of the autoimmune response both problems and opportunities in the process of un-
when combined with genes that mediate the loss of raveling the genetics of human lupus. The presence of
tolerance to nuclear autoantigens. The final class of suppressive modifiers within specific families or ethnic
lupus susceptibility genes, represented by Sle6 in our groups would conceal the phenotypes of potent suscep-
model system, contains genes that potentiate end organ tibility genes in both linkage and allele-association stud-
damage. Theoretically, end organ damage could be en- ies. If such effects are prevalent, then a definitive identifi-
hanced by a variety of molecular mechanisms, including cation of the genes involved may be quite difficult. The
genes that modify immune effector functions (such as genetic and phenotypic similarities of autoimmune lupus
complement components [Botto et al., 1998]) and those nephritis in humans and mice suggest that a coordinate
that modify the end organ itself. Our analysis of Sle6 approach may be the most productive strategy avail-
indicates that it strongly impacts the development of able. The congenic strains that we have produced pro-
glomerulonephritis but has little or no impact on autoan- vide the tools with which to unravel the intricacies of
tibody production, consistent with a component pheno- the epistatic interactions, and, ultimately, to identify the
type in the third genetic pathway. genes involved. The identification of suppressive modifi-
Finally, the results presented here indicate that a se- ers in mice could be used subsequently to stratify fami-
lies and ethnic groups in human linkage analysis, sinceries of suppressive genes must be added to this model.
Immunity
138
30 sec at 728C). PCR products were visualized on ethidium-bromidepolymorphisms at these loci may delineate epistatic in-
stained 5% agarose gels.teractions masking susceptibility loci. In addition, the
presence of such potent suppressive modifiers in this
Linkage Analysisdisease suggests that a thorough understanding of the
Linkage groups were developed using MAPMAKER-EXP (Lander et
genetic pathways involved may identify strategies for al., 1987) as described previously (Morel et al., 1994). Statistical
therapeutic intervention. The profound impact of geno- analyses of linkage were performed as described (Morel et al., 1994).
mic context on the expression of fatal lupus in this To control for potential distortions in segregation ratios, the ex-
pected genotypic frequencies for each SSLP marker were correctedmouse model supports the feasibility of identifying ap-
by determining the genotypic ratios in a sample of 133 (B6.NZMc1 3propriate genetic targets for the development of effec-
NZW)F1 3 NZW unaffected progeny. The only genomic region intive therapies.
which segregation distortion reached significant levels was in the
interval containing the pink-eye dilute locus on chromosome 7.
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